Rapid and comprehensive determination of cytochrome P450 CYP2D6 poor metabolizer genotypes by multiplex polymerase chain reaction

Human Mutation

Volumn 16, Issue 1, 2000, Pages 77-85

  Roberts, Rebecca ^a   Sullivan, Patrick ^a,b   Joyce, Peter ^a   Kennedy, Martin A ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

CYP2D6; Drug metabolism; Mutation detection; Poor metabolizers

Indexed keywords

DEBRISOQUINE 4 HYDROXYLASE;

ARTICLE; ENZYME POLYMORPHISM; GENE FREQUENCY; GENE LOCUS; GENE MUTATION; GENETIC VARIABILITY; HUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; XENOBIOTIC METABOLISM;

ALLELES; BLOOD; CYTOCHROME P-450 CYP2D6; DNA; DNA PRIMERS; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENOTYPE; HUMANS; PHENOTYPE; POLYMERASE CHAIN REACTION;

EID: 0033921510     PISSN: 10597794     EISSN: None     Source Type: Journal    
DOI: 10.1002/1098-1004(200007)16:1<77::AID-HUMU13>3.0.CO;2-T     Document Type: Article

References (31)

1. Bertilsson L, Dahl ML, Sjoqvist F, Aberg-Wistedt A, Humble M, Johansson I, Lundqvist E, Ingelman-Sundberg M. 1993. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet 341:63.
2. Breslauer KJ, Frank R, Blocker H, Marky LA. 1986. Predicting DNA duplex stability from the base sequence. Proc Natl Acad Sci USA 83:3746-3750.
3. Brosen K, Gram LF. 1989. Clinical significance of the sparteine/ debrisoquine oxidation polymorphism. European Journal of Clinical Pharmacology 36:537-547.
4. Chen S, Chou WH, Blouin RA, Mao Z, Humphries LL, Meek QC, Neill JR, Martin WL, Hays LR, Wedlund PJ. 1996. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther 60:522-534.
5. Ciulla T, Slar R, Hauser S. 1988. A simple method for DNA purification from peripheral blood. Anal Biochem 174:485-488.
6. Daly AK, Brockmoller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, Huang JD, Idle JR, Ingelman-Sundberg M, Ishizaki T, Jacqz-Aigrain E, Meyer UA, Nebert DW, Steen VM, Wolf CR, Zanger UM. 1996. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 6:193-201.
7. Dracopoli N, Haines J, Korf B, Moir D, Morton C, Seidman C, Seidman J, Smith D. 1994. In: Boyle A, editor. Current protocols in human genetics. New York: John Wiley & Sons, Inc.
8. Eichelbaum M, Evert B. 1996. Influence of pharmacogenetics on drug disposition and response. Clin Exp Pharmacol Physiol 23:983-985.
9. Fjordside L, Jeppesen U, Eap CB, Powell K, Baumann P, Brosen K. 1999. The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine. Pharmacogenetics 9:55-60.
10. Griese EU, Zanger UM, Brudermanns U, Gaedigk A, Mikus G, Morike K, Stuven T, Eichelbaum M. 1998. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 8:15-26.
11. Heim M, Meyer UA. 1990. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 336:529-32.
12. Heim MH, Meyer UA. 1992. Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6. Genomics 14:49-58.
13. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjoqvist F, Ingelman-Sundberg M. 1993. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Nad Acad Sci USA 90:11825-11829.
14. Kennedy M, Morris C, Hollings P, Fitzgerald P. 1989. Involvement of immunoglobulin heavy- and light-chain (kappa) gene clusters in a human B-cell translocation, t(2;14). Cytogenet Cell Genet 52:50-56.
15. Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ. 1989. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet 45: 889-904.
16. Kroemer HK, Eichelbaum M. 1995. "It's the genes, stupid." Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci 56:2285-2298.
17. Kwok S, Kellogg DE, McKinney N, Spasic D, Goda L, Levenson C, Sninsky JJ. 1990. Effects of primer-template mismatches on the polymerase chain reaction: human immunodeficiency virus type 1 model studies. Nucleic Acids Res 18:999-1005.
18. Lahiri DK, Nurnberger JI Jr. 1991. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res 19:5444.
19. Linder MW, Prough RA, Valdes R Jr. 1997. Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. Clin Chem 43:254-266.
20. Marez D, Legrand M, Sabbagh N, Guidice JM, Spire C, Lafitte JJ, Meyer UA, Broly F. 1997. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 7:193-202.
21. Marez-Allorge D, Ellis SW, Lo Guidice JM, Tucker GT, Broly F. 1999. A rare G(2061) insertion affecting the open reading frame of CYP2D6 and responsible for the poor metabolizer phenotype. Pharmacogenetics 9:393-396.
22. Meyer UA, Amrein R, Balant LP, Bertilsson L, Eichelbaum M, Guentert TW, Henauer S, Jackson P, Laux G, Mikkelsen H, Peck C, Pollock BG, Priest R, Sjoqvist F, Delini-Stula A. 1996. Antidepressants and drug-metabolizing enzymes - expert group report. Acta Psychiatr Scand 93:71-79.
23. Morgan MY, Reshef R, Shah RR, Oates NS, Smith RL, Sherlock S. 1984. Impaired oxidation of debrisoquine in patients with perhexiline liver injury. Gut 25:1057-1064.
24. Nebert DW. 1997. Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist? Am J Hum Genet 60:265-271.
25. Poulsen L, Brosen K, Arendt-Nielsen L, Gram LF, Elbaek K, Sindrup SH. 1996. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. Eur J Clin Pharmacol 51:289-295.
26. Richards B, Skoletsky J, Shuber AP, Balfour R, Stem RC, Dorkin HL, Parad RB, Witt D, Klinger KW. 1993. Multiplex PCR amplification from the CFTR gene using DNA prepared from buccal brushes/swabs. Hum Molec Genet 2:159-163.
27. Sachse C, Brockmoller J, Bauer S, Roots I. 1997. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60: 284-295.
28. Shah RR, Oates NS, Idle JR, Smith RL, Lockhart JD. 1982. Impaired oxidation of debrisoquine in patients with perhexiline neuropathy. British Medical Journal Clinical Research Ed 284:295-299.
29. Skoda RC, Gonzalez FJ, Demierre A, Meyer UA. 1988. Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci USA 85:5240-5243.
30. Spina E, Ancione M, Di Rosa AE, Meduri M, Caputi AP. 1992. Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects. European Journal of Clinical Pharmacology 42:347-348.
31. Stuven T, Griese EU, Kroemer HK, Eichelbaum M, Zanger UM. 1996. Rapid detection of CYP2D6 null alleles by long distance- and multiplex-polymerase chain reaction. Pharmacogenetics 6:417-421.